HR Execs on the Move

Cobb Psychotherapy LCSW

www.cobbpsychotherapy.com

 
Cobb Psychotherapy is a group private practice providing mental health counseling services. Our therapists practice a range of interventions including evidence-based therapies traditional talk therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Draximage

Draximage is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Azopharma Contract Pharmaceutical Services

Azopharma Contract Pharmaceutical Services is a Miramar, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts.

Advanced Orthopedics of Oklahoma

At Advanced Orthopedics of Oklahoma, our specialty-trained orthopedic doctors and staff deliver the expert, compassionate care needed to heal, recover, and advance throughout Oklahoma in Tulsa, Claremore, Bixby, McAlester.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.